Purpose: We conducted a survey of providers to assess for practice patterns in diagnosing and treating new-onset refractory status epilepticus (NORSE). NORSE is the occurrence of prolonged seizures that are not responsive to initial therapies in otherwise healthy individuals without obvious cause on initial presentation. This entity is thought to have multiple etiologies, including autoimmune. Method: A 29-question electronic survey was sent to providers included in the Neurocritical Care Society emailing list. Questions regarded responders' demographics, existing institutional practice protocols, diagnostic work-up, therapeutic management and expected outcomes in NORSE. Responses were collected from October 23, 2014, to November 25, 2014. Results: There were 107 respondents out of 1334 (8%). CT head, continuous EEG, lumbar puncture and microbe serologies were suggested within 24 h of presentation as part of a diagnostic work-up. MRI brain, autoimmune work-up (systemic and anti-neuronal antibodies) and cytology/flow cytometry were favored later in the course. About 25% of providers would never perform an autoimmune work-up in this setting. Initial treatment included up to 3 anticonvulsants (including one anesthetic), followed by additional anticonvulsants/anesthetics along with antimicrobials, followed by steroids, plasma exchange, hypothermia and ketogenic diet. Many respondents would never use IV immunoglobulin or steroid-sparing immunosuppressants (29% and 42%, respectively) for NORSE. Conclusions: This survey could serve as the foundation for development of a standardized approach for the diagnosis and treatment of NORSE.
Introduction
New-onset refractory status epilepticus (NORSE) is a syndrome of prolonged seizures that typically develops in otherwise healthy, young individuals without a history of epilepsy or obvious initial cause. The term was first coined in a case series of 7 young women with prior good health who developed refractory status epilepticus (RSE) with an extensive, negative diagnostic work-up and poor outcome [1] . While the incidence of RSE is estimated between 9-43% of all episodes of SE, no such data exists for NORSE [2, 3] . Patients with NORSE experience prolonged lengths of stay in the hospital/intensive care unit (ICU) and myriad complications with poor short and long-term outcomes [1, [4] [5] [6] . In one study, the average duration of NORSE was 36 days, and the average length of stay in the ICU was 33.5 days [5] . The costs of NORSE are substantial both in terms of functional outcome and healthcare dollars [1, 5, 7, 8] .
The etiology of NORSE is often presumed to be due to viral encephalitis, but more than half of cases remain cryptogenic despite extensive investigations [4, 5] . In retrospective case series, autoimmune or paraneoplastic causes of encephalitis with RSE make up the majority of cases with an established etiology, and a proportion of cryptogenic cases may be caused by antibodies yet to be described [4] . Immunotherapy has been proposed as empiric treatment for RSE and emerging evidence suggests that this may benefit patients with NORSE specifically [5, 6, 9, 10] . Currently, there are no published protocols to guide the diagnostic work-up of NORSE, and while there are general recommendations for the management of RSE, no specific guidelines address which treatment options should be given and when, particularly when it comes to immunotherapy [11] . We sought to identify practice patterns in the diagnosis and management of NORSE in order to identify commonalities that could be used to standardize the approach to these patients and to identify areas of uncertainty that require further study.
Methods
A 29-question survey (SurveyMonkey Inc.; Palo Alto, California, USA) was electronically distributed to 1334 members of the Neurocritical Care Society. Responses were collected over a onemonth period from October 2014 to November 2014. The survey was completed anonymously, and contained questions regarding responder demographics, existing institutional practice protocols, diagnostic work-up and therapeutic management of NORSE. Demographics included years in practice, training background, practice setting and geographic location. Questions about diagnostic work-up were designed to explore both the differential diagnosis of NORSE as well as the timing of studies used by providers to work through this differential. The timing of diagnostic studies was divided into 4 categories: within 24 h, 24-72 h, >72 h, or never unless indicated for another reason. Therapeutic management decisions were evaluated using questions to elicit the timing of both antiepileptic drug (AED) and immunomodulatory treatments, their specific dosages and frequencies and different scenarios that would prompt their initiation. Finally, we asked providers to choose between 0 to 100% probability that a specific outcome would occur based on provider experience and expectations. This clinical practice pattern survey was exempt from human subjects research approval after review by the Emory University IRB.
Results

Respondent Demographics/Institutional Protocol
Seventy-three percent of respondents (78/107) completed the survey in its entirety. The median number of years in practice was 8 years [interquartile range (IQR) 4-15.5). The majority of respondents reported that they practice in academic settings (79%; 85/107) and had been trained in critical care neurology (59%; 63/107) or critical care medicine (22%; 24/107). Two percent (2/107) of respondents had epilepsy sub-specialty training. More than three-quarters (78%; 82/105) of respondents indicated that they practice in the United States, while 22% (23/105) practice internationally. Sixty-three percent (64/101) reported that their institution does not have a diagnostic or therapeutic protocol in place for NORSE. A minority reported having diagnostic protocols for CSF (10%; 10/101), serum (13%; 13/101) and imaging studies (16%; 16/101).
Diagnostic Approach
Within 24 h, most practitioners obtain a non-contrast head CT (100%), continuous EEG (89%) and lumbar puncture (LP; 76%). Microbe serologies, particularly viral studies, are sent during this period by 42%. Between 24-72 h, 55% obtain a brain MRI. More than one-third also begin an autoimmune work-up (42%), antineuronal antibodies (40%), and cytology/flow cytometry (35%) during this period. After 72 h, no clear consensus emerged regarding further work-up. The majority of practitioners reported that they would never obtain a SPECT, brain/body PET, genetic testing or angiogram without an additional indication. Similarly, heavy metals, porphyrins, ovarian/testicular ultrasound, 14-3-3 protein, and neoplastic screening CT of the chest, abdomen, and pelvis were not regularly considered as part of the work-up (Fig. 1) .
About one quarter of respondents indicated that they do not send autoimmune serologies or anti-neuronal antibodies in NORSE patients unless indicated for another reason. Of those who send autoimmune serologies, the most common initial work-up included antinuclear antibody (ANA), double-stranded (ds) DNA, rheumatoid factor, anti-neutrophil cytoplasmic antibody (ANCA), lupus anticoagulant, antiphospholipid antibody, anti-Ro/SSA and anti-La/SSB. The most commonly reported extended autoimmune panel included anti-endomysial, anti-transglutaminase, anti-gliadin, anti-thyroid peroxidase, anti-thyroglobulin, acetylcholine receptor muscle binding/ganglionic neuronal antibodies and a number of anti-neuronal antibodies such as anti-glutamic acid decarboxylase (GAD) 65, anti-neuronal nuclear antibody (ANNA) Fig. 1 . Diagnostic Approach to NORSE. Survey respondents categorized each diagnostic study into time at which they would obtain the test in the setting of NORSE: <24 h, 24-72 h, >72 h, or never unless indicated for another reason. type 1(anti-Hu), ANNA2 (anti-Ri), ANNA3, anti-voltage-gated potassium channel and NMDA (Fig. 2) . Seventy-two percent (61/85) of providers reported that they obtain both CSF and serum specimens for anti-neuronal antibody testing compared to 13% (11/ 85) for CSF alone and 6% (5/85) for serum alone.
Initial serum and CSF microbiology studies sent by providers include herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV) PCR tests, and tests for parasites and fungal microbes such as Toxoplasma gondii and Cryptococcus neoformans (Figs. 3 and 4). CSF West Nile Virus (WNV) is sent by 57%. The majority reported that they evaluate for Treponema pallidum, both serum rapid plasma reagin (RPR, 77%) and CSF venereal disease research laboratory (VDRL, 71%), and send serum HIV (80%). As part of an extended work-up, one-half send Borrelia burgdorferi (Lyme, 53%) and Mycoplasma pneumoniae (53%) serologies, whereas CSF Lyme ELISA was usually included as an initial study (58%). The extended CSF work-up included primarily arboviruses, such as the St. Louis encephalitis (62%) and equine encephalitis viruses (66%), as well as John Cunningham (JC) virus (80%) and angiotensin-converting enzyme (ACE) level (69%).
Ninety-two percent of respondents reported that they would consider brain biopsy if a detailed work-up was unrevealing: 55% (46/84) would consider biopsy of a contrast-enhanced, superficial cortical lesion, and 29% (24/84) would consider a biopsy of any contrast-enhanced lesion seen on MRI regardless of location.
Therapeutic Approach
For a patient with NORSE refractory to an initial anesthetic agent, respondents indicated they would first administer: additional AEDs (77%), additional anesthetics (52%), and antimicrobials (37%). Steroids (24%) were considered next followed by plasma exchange (PLEX; 28%). A five-day course of pulse-dose methylprednisolone was the most commonly used steroid regimen and typically started immediately in patients with a suspected autoimmune or paraneoplastic etiology, or when clinical symptoms, including RSE, do not improve within 1 week. Following immunotherapy, respondents reported using the ketogenic diet (41%) or hypothermia (25%).
Nearly one-third (29%) of respondents reported they would never use IVIG in the setting of NORSE; 24% would not use PLEX. Further, 29% eventually transition to steroid-sparing immunosuppressants. Most respondents do not consider transcranial magnetic stimulation, electroconvulsive therapy, or epilepsy surgery unless indicated for another reason (Fig. 5) .
Respondents were asked to select non-continuous, bolus-dose or oral anticonvulsants that they would use as adjunct treatment for ongoing RSE and rank the order in which they would initiate them. Most selected benzodiazepines first: lorazepam (93%; 39/ 42), midazolam (32%; 12/38) and diazepam (67%; 4/6) followed by fosphenytoin (55%; 30/55), phenytoin (38%; 10/26) and carbamazepine (33%; 2/6). Levetiracetam (34%; 24/71) was most commonly added third, and lacosamide (29%; 17/58) was fourth.
Efficacy was ranked the most influential determinant when choosing AEDs (64%) followed second by drug interactions (43%) and third by hemodynamic instability (36%). Respondents selected anesthetics in the following order: midazolam, propofol, pentobarbital/thiopental, and ketamine.
Expectation of Outcomes
Respondents were asked to provide a gross probability for outcomes in NORSE from 0 to 100%, based on expectations formed from their personal clinical experience. The median mortality rate was estimated to be 33% (IQR = 30-58), chance of functional 
Discussion
The goal of this survey was to examine current practices in the diagnosis and treatment of NORSE and identify patterns among experts that could inform a rational approach to this challenging syndrome. We found that nearly two-thirds of institutions represented by our sample did not employ a protocol to evaluate patients with NORSE. Also, one-quarter of respondents would not perform an autoimmune or paraneoplastic evaluation in a patient without a suggestive history or physical exam, and most sent antineuronal antibody studies only as part of an extended work-up. This survey provides data that suggests that a standardized approach may be feasible and has the capacity to decrease both the time to diagnosis and treatment, particularly immunomodulatory therapies, which may be important to improving the overall outcome of patients with NORSE.
Diagnostic Approach
The most consistently tested causative agent was HSV, for which 99% tested CSF via PCR in the first 24 h. HSV is the most commonly diagnosed viral encephalitis and there is an established role for early treatment as delays beyond 48 h after hospital admission can be associated with a worse prognosis. Thus, it is often standard practice for anti-viral therapies to be started empirically and continued if diagnosis is confirmed [12] . Ninetytwo percent tested VZV within this same time period. We found that Enterovirus is less often tested at 61% compared to HSV and VZV, despite the combination of the three making up the vast majority of diagnosed viral encephalitides [12] . Infectious etiologies with important public health implications, such as WNV and mycobacterium tuberculosis, as well as treatable disease like mycoplasma pneumoniae, were less frequently tested for and not included as part of the initial work-up.
We found that one-quarter of respondents would never perform an autoimmune or paraneoplastic work-up in the setting of NORSE unless indicated for another reason. This could result in a significant number of missed diagnoses as a recent multiinstitutional retrospective review of 130 NORSE cases found that autoimmune and paraneoplastic were the most common identifiable etiologies at 19% and 18%, respectively, with 52% remaining cryptogenic [4] . Further, the favored initial autoimmune work-up primarily encompassed rheumatologic antibodies, e.g., ANA, dsDNA, rheumatoid factor, ANCA, etc., while an expanded workup included anti-neuronal antibodies. Ideally, autoimmune and paraneoplastic evaluations would coincide, as there is no evidence that one is more prevalent in NORSE than the other. This may be due to the higher expense of the anti-neuronal/paraneoplastic antibody panels or long wait times for results after sending the specimens to the few labs that are equipped to perform the analysis.
There was a preference of sending a serum and CSF specimen for the anti-neuronal/paraneoplastic work-up, which the majority of providers (72%) agreed was more appropriate than sending any one specimen alone. This is consistent with increased sensitivity for NMDA receptor antibodies when both CSF and serum are tested (sensitivity 100% and 85.6%, respectively) [10, 13] . Some providers may desire to avoid subjecting a patient to a repeat LP, after an initial one that was performed within 24 h to rule out infectious etiologies. However, repeat LP may ultimately be necessary in some situations even to fully rule out infectious causes as the HSV CSF PCR sensitivity increases 4 or more days after symptom onset [14] .
A majority of respondents would not perform a malignancy work-up, e.g., CT, PET, or ultrasound, in the setting of NORSE despite paraneoplastic disorders (PND) being a commonly diagnosed etiology [4] . A neoplastic work-up would be particularly important in the setting of a positive anti-neuronal antibody, especially one with a known association with tumor (e.g., NMDA receptor antibodies and ovarian teratoma), as treatment of the tumor may be therapeutic/curative for the PND [15] . There may exist some system barriers to obtaining inpatient PET scans, as RSE likely would not be a recognized indication. However, in situations where the etiology of NORSE is cryptogenic or the clinical scenario points to PND, then this work-up would be warranted [15] .
Based on our survey of, expert opinion on the diagnostic approach to NORSE, studies performed within the initial 24 h of presentation include CT head, continuous EEG, LP and microbe serologies that include HSV, VZV, and bacterial evaluation. Thereafter, MRI brain followed by repeat LP to evaluate for an autoimmune or neoplastic cause should be obtained. Additional work-up should be individualized to the patient and based on clinical context.
Therapeutic Approach
The majority of respondents agreed that once SE became refractory to anesthetics, additional anticonvulsants/anesthetics along with antimicrobials should be considered next, followed by steroids, PLEX, hypothermia and ketogenic diet. Similar to the diagnostic approach, this order places high emphasis on early treatment of infectious etiologies, and the necessity of controlling RSE rapidly in order to minimize the risk of permanent brain damage and functional impairment. This correlates well with existing suggested protocols for treatment of refractory and superrefractory SE [11, 16] .
Most respondents would never consider IVIG (29%); although, 24% would use IVIG as a third-line intervention similar to PLEX (28%). Also, 42% would never consider steroid-sparing immunosuppressants (e.g., rituximab or cyclophosphamide) for NORSE unless another indication arose. Eighteen percent would never consider steroids, and 24% would never consider PLEX. These findings are somewhat discordant with the fact that the majority of providers would initiate immunotherapies immediately or within 1 week if there was no improvement (46% and 45%, respectively). The survey also revealed that there is great variance in the order in which providers would initiate immunotherapy versus other therapies for RSE. These findings are in contrast to the fact that a number of cases of NORSE have been treated with immunotherapy with successful cessation of SE; although, functional outcomes are variable [4] [5] [6] 9] . The rationale behind the use of immunotherapy in NORSE is based upon the idea that an underlying pathogenic or inflammatory-provoking autoantibody make up a majority of these cases [4] . Furthermore, there is increasing evidence pointing to epileptogenesis as a result of inflammation from seizures [17, 18] . In the setting of SE, it is thought that inflammatory mediators are released promoting neuronal hyperexcitability and continued seizures, inevitably causing it to become more refractory [19, 20, 21] . The average time until the start of immunotherapy for NORSE in a combination of studies was 14.5 days, which is a significant delay and may contribute to the overall poor outcomes in this setting [6, 9] .
More studies are needed to address the efficacy of immunotherapies in NORSE.
Based on this survey, expert opinion favors treating RSE by first adding additional anticonvulsants or anesthetics before adding immunomodulatory therapies. Treatment of RSE should proceed quickly to resolution of seizures or burst-suppression. Although early immunotherapy would not be considered at odds with current consensus and could be synergistic in treating symptomatic seizures, the majority of respondents prefer to delay instituting an immunotherapy until an abnormal antibody has been defined. However we favor the approach of starting immunotherapy empirically as soon as the work-up for antibodies has been sent without delaying treatment for several days or even weeks while waiting for confirmatory results.
Expectation of Outcomes
Despite treatment with immunotherapies, long-term outcomes are variable and usually include a degree of impaired cognition along with epilepsy. In 4 cases series (n = 4-7), the rate of mortality ranged from 17 to 100%, and the rate of chronic epilepsy or encephalopathy from 29 to 83% [1, 5, 6, 9] . In a large, multi-center retrospective case series (n = 130), 62% (77 cases) had poor outcome at discharge defined as Modified Rankin Scale of 4-6, there was a 22% rate of mortality (28 cases), and 92% developed epilepsy and/or continued AEDs [4] . This differed from our providers' expectations mainly in the rate of epilepsy at 60% and less so with rate of mortality at 33%, with poor outcome being similar at 60%.
Limitations
The most obvious limitation was the relatively low response rate of 8%; thus, providing a small sampling on the clinical practice of the providers that primarily manage NORSE. Not all of the respondents fully completed the survey, likely due to survey fatigue, which resulted in a variable percent of responses across questions. Importantly, the majority of those who did respond were neuro-intensivists without sub-specialty epilepsy training, and members of an active academic society, the Neurocritical Care Society, which may bias the sample towards more aggressive testing or treatment. Survey questions were devised by study authors, but not externally validated, and interpretation was left to the individual respondents. Study responses were not systematically evaluated for either inter-rater or intra-rater reliability, which may create additional bias. Our analysis intended to qualitatively describe these responses in order to provide direction to the field rather than inferring specific bestquality practices.
Conclusion
NORSE is clinically challenging to diagnose and manage. Although increasing data suggests that autoimmune and paraneoplastic-mediated etiologies are the most commonly identified, current diagnostic and therapeutic strategies employed by the majority of practitioners caring for patients with NORSE focus on infectious causes. Therefore, there is a need for standardized approaches to detect and treat immune-mediated causes of NORSE in a more timely fashion.
